Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6013397 | 0.89 | ESR2 (0.50) | L3MBTL1MAPTESR2ALDH1A1CYP2C9 | |
| SCHEMBL6013398 | 0.89 | ESR2 (0.50) | L3MBTL1MAPTESR2ALDH1A1CYP2C9 | |
| SCHEMBL26649191 | 0.84 | ESR2 (0.44) | MAPTESR2ALDH1A1BCHE | |
| SCHEMBL14127784 | 0.81 | ESR2 (0.46) | L3MBTL1MAPTESR2ALDH1A1BCHE | |
| SCHEMBL4086500 | 0.78 | KMT2A (0.44) | L3MBTL1ESR2KMT2A | |
| SCHEMBL22070710 | 0.77 | HPGD (0.46) | L3MBTL1MAPTESR2ALDH1A1MEN1 | |
| SCHEMBL21199846 | 0.77 | ESR2 (0.46) | MAPTESR2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30686540 | 0.75 | HTR2C (0.51) | ESR2CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL1922424 | 0.75 | KMT2A (0.42) | L3MBTL1MAPTESR2BCHEKMT2A | |
| SCHEMBL29240499 | 0.73 | ESR2 (0.56) | L3MBTL1MAPTESR2ALDH1A1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032555-B1 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER LAMBERT CO (US) | 2006-04-12 | — | — | EP | claimed |
| US-20050159487-A1 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | BRYANS JUSTIN S (GB) | 2005-07-21 | — | — | US | claimed |
| US-20030220397-A1 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-11-27 | — | — | US | claimed |
| EP-1032555-A1 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1999021824-A1 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-05-06 | — | — | WO | claimed |
| US-7122678-B2 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | WARNER-LAMBERT COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1032555-B1 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER LAMBERT CO (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1572184-A1 | GABAPENTIN ANALOGUES FOR FIBROMYALGIA AND OTHER RELATED DISORDERS | WARNER-LAMBERT COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6921835-B2 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | WARNER LAMBERT COMPANY (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050159487-A1 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | BRYANS JUSTIN S (GB) | 2005-07-21 | — | — | US | disclosed |
| US-20040180959-A1 | Gabapentin analogues for fibromy algia and concomitant disorders | DOOLEY DAVID JAMES (US) | 2004-09-16 | — | — | US | disclosed |
| WO-2004054564-A1 | GABAPENTIN ANALOGUES FOR FIBROMYALGIA AND OTHER RELATED DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054564-A1 | GABAPENTIN ANALOGUES FOR FIBROMYALGIA AND OTHER RELATED DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20030220397-A1 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-11-27 | — | — | US | disclosed |
| US-6635673-B1 | 1-Aminomethyl-3,4-dimethyl-cyclopentyl acetic acid; epilepsy; neurodegenerative, neuropathological and gastrointestinal disorders; depression, anxiety, panic, pain | WARNER-LAMBERT COMPANY | 2003-10-21 | — | — | US | disclosed |
| EP-1032555-A1 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999021824-A1 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220397-A1 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | APC, VIP, NPSR1 | L3MBTL1 4806/4885MAPT 573/4885ESR2 3468/4885 |
| US-20040180959-A1 | Gabapentin analogues for fibromy algia and concomitant disorders | PKD2, CACNA1S, CACNA1B | L3MBTL1 4492/4885MAPT 2006/4885ESR2 3217/4885 |
| US-20050159487-A1 | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | APC, VIP, NPSR1 | L3MBTL1 4806/4885MAPT 573/4885ESR2 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.